

For Research Use Only

anti-CTLA4 recombinant VHH, FITC Plus



www.ptgcn.com

Catalog Number: FITC-ctl

Basic Information

Catalog Number:
FITC-ctl

Applications:
FC, IF

Host:
Alpaca

Conjugate:
FITC Plus

Type:

Nanobody

Class:

Recombinant

RRID:

AB_3101937

Molecular Weight:

14.005 kDa

Description

FITC-ctl targets CTLA4 in FC and IF applications and shows reactivity with Human samples.

Affinity

22 nM

Excitation/Emission Maxima Wavelengths

495 nm / 524 nm

Background

CTLA-4, also known as CD152, belonging to the immunoglobulin superfamily, is primarily found on activated T cells and regulatory T cells (Tregs). CTLA-4 is closely related to the T-cell costimulatory CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 acts as a negative regulatory molecule of T-cell responses. Besides the full-length transmembrane form, CTLA-4 also exists in a truncated soluble form (sCTLA-4).

Storage

Storage:

Store at -20°C

Storage Buffer:

500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide

For technical support and original validation data for this product please contact:


T: 4006900926

E: Proteintech-CN@ptglab.com


W: www.ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data




1x10⁶ HEK CTLA4 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg FITC Plus conjugated-CTLA4 VHH (FITC-ctl). Cells were not fixed.




1x10⁶ PHA-treated (3d) human PBMCs were surface stained with CL405 CD3 (CL405-65151) then fixed and permeabilized and stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl). Right: 1x10⁶ PHA-treated (3d) human PBMCs were fixed and permeabilized then stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1x10⁶ untreated human PBMCs were fixed and permeabilized then stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transcription Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.



Left: 1x10⁶ PHA-treated (3d) human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) and CL405 CD3 (CL405-65151). Right: 1x10⁶ PHA-treated (3d) human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1x10⁶ untreated human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transcription Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.



HeLa cells transfected with human CTLA-4 were immunostained with FITC Plus conjugated-CTLA4 VHH (FITC-ctl) (1:500, green). Nuclei were stained with DAPI (blue). Epifluorescence images were acquired with a 40x objective and post-processed. Comment: Immunostaining with FITC-ctl can be performed live or after formaldehyde fixation.



Left: 1x10⁶ PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) and CL750 CD3 (CL750-65151). Right: 1x10⁶ PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1x10⁶ untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.